Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Mammary cells with active Wnt signaling resist ErbB2-induced tumorigenesis.

Bu W, Zhang X, Dai H, Huang S, Li Y.

PLoS One. 2013 Nov 12;8(11):e78720. doi: 10.1371/journal.pone.0078720. eCollection 2013.

2.

Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models.

Du Z, Podsypanina K, Huang S, McGrath A, Toneff MJ, Bogoslovskaia E, Zhang X, Moraes RC, Fluck M, Allred DC, Lewis MT, Varmus HE, Li Y.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17396-401. Epub 2006 Nov 7.

3.

Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis.

Zhang J, Li Y, Liu Q, Lu W, Bu G.

Oncogene. 2010 Jan 28;29(4):539-49. doi: 10.1038/onc.2009.339. Epub 2009 Nov 2.

4.

Krt6a-positive mammary epithelial progenitors are not at increased vulnerability to tumorigenesis initiated by ErbB2.

Holloway KR, Sinha VC, Toneff MJ, Bu W, Hilsenbeck SG, Li Y.

PLoS One. 2015 Jan 30;10(1):e0117239. doi: 10.1371/journal.pone.0117239. eCollection 2015.

5.

Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.

Landis MD, Seachrist DD, Abdul-Karim FW, Keri RA.

Oncogene. 2006 Jun 1;25(23):3325-34. Epub 2006 Jan 23.

6.

Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.

Nguyen A, Rosner A, Milovanovic T, Hope C, Planutis K, Saha B, Chaiwun B, Lin F, Imam SA, Marsh JL, Holcombe RF.

Int J Oncol. 2005 Oct;27(4):949-56.

PMID:
16142310
7.

The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.

Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, Jackson D, Bruckheimer E, Muraoka-Cook RS, Chen J.

J Clin Invest. 2008 Jan;118(1):64-78.

8.

ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas.

Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, Gendler SJ.

J Biol Chem. 2002 Jun 21;277(25):22692-8. Epub 2002 Apr 11.

9.

Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer.

Hallett RM, Kondratyev MK, Giacomelli AO, Nixon AM, Girgis-Gabardo A, Ilieva D, Hassell JA.

PLoS One. 2012;7(3):e33976. doi: 10.1371/journal.pone.0033976. Epub 2012 Mar 28.

10.

p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.

Cabodi S, Tinnirello A, Di Stefano P, Bisarò B, Ambrosino E, Castellano I, Sapino A, Arisio R, Cavallo F, Forni G, Glukhova M, Silengo L, Altruda F, Turco E, Tarone G, Defilippi P.

Cancer Res. 2006 May 1;66(9):4672-80.

11.

ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss.

Lozy F, Cai-McRae X, Teplova I, Price S, Reddy A, Bhanot G, Ganesan S, Vazquez A, Karantza V.

Autophagy. 2014 Apr;10(4):662-76. doi: 10.4161/auto.27867. Epub 2014 Jan 30.

12.

Inhibition of eIF2alpha dephosphorylation inhibits ErbB2-induced deregulation of mammary acinar morphogenesis.

Sequeira SJ, Wen HC, Avivar-Valderas A, Farias EF, Aguirre-Ghiso JA.

BMC Cell Biol. 2009 Sep 15;10:64. doi: 10.1186/1471-2121-10-64.

13.

ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells.

Muraoka RS, Lenferink AE, Law B, Hamilton E, Brantley DM, Roebuck LR, Arteaga CL.

Mol Cell Biol. 2002 Apr;22(7):2204-19.

14.

Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.

Peng M, Ball-Kell SM, Tyner AL.

Cell Death Dis. 2015 Aug 6;6:e1848. doi: 10.1038/cddis.2015.210.

15.

A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis.

Dearth RK, Kuiatse I, Wang YF, Liao L, Hilsenbeck SG, Brown PH, Xu J, Lee AV.

BMC Cancer. 2011 Aug 25;11:377. doi: 10.1186/1471-2407-11-377.

16.

Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.

Zelazny E, Li B, Anagnostopoulos AM, Coleman A, Perkins AS.

Exp Mol Pathol. 2001 Jun;70(3):183-93.

PMID:
11417997
17.

Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors.

Shen Q, Uray IP, Li Y, Zhang Y, Hill J, Xu XC, Young MR, Gunther EJ, Hilsenbeck SG, Colburn NH, Chodosh LA, Brown PH.

Cancer Prev Res (Phila). 2008 Jun;1(1):45-55. doi: 10.1158/1940-6207.CAPR-08-0034. Epub 2008 Mar 31.

18.

Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis.

Lahlou H, Müller T, Sanguin-Gendreau V, Birchmeier C, Muller WJ.

Cancer Res. 2012 Jun 15;72(12):3080-90. doi: 10.1158/0008-5472.CAN-11-3513. Epub 2012 Jun 4.

19.

Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice.

Hodgson MC, Vanostran G, Alghamdi S, Poppiti RJ, Agoulnik AI, Agoulnik IU.

PLoS One. 2013 Apr 8;8(4):e60455. doi: 10.1371/journal.pone.0060455. Print 2013.

20.
Items per page

Supplemental Content

Write to the Help Desk